EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Discovery and validation of a robust 11-gene prognostic signature via integrative multi-omics profiling in VD-CAG-treated non-M3 AML

Jirui Tang, Kun Yang, Ying Zhang, Yuqian Tang, Yankun Yang, Qin Li, Xuemei Wang, Yuping Gong

Frontiers in Oncology · 19.05.2026 · 16

DOI: 10.3389/fonc.2026.1801526 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 19.05.2026. Verfasst von Jirui Tang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, West China Hospital, Sichuan University, Chengdu, China. Die Arbeit nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

While the venetoclax-based VD-CAG regimen has shown promising efficacy in acute myeloid leukemia (AML), its underlying molecular response mechanisms remain poorly understood, and robust prognostic biomarkers for non-M3 AML treated with this regimen are lacking. This study aimed to elucidate the molecular alterations associated with VD-CAG treatment response, and to identify and validate robust prognostic biomarkers to improve risk stratification for non-M3 AML patients.

Methods

This study enrolled 15 non-M3 AML patients receiving VD-CAG induction therapy, and conducted integrative multi-omics profiling of their bone marrow samples: RNA sequencing was performed on 10 pairs of pre- and post-treatment samples, while data-independent acquisition (DIA) proteomics was applied to another 5 paired samples. Weighted gene co-expression network analysis (WGCNA) was used to identify gene modules correlated with composite complete remission. A prognostic signature was further derived using Least Absolute Shrinkage and Selection Operator (LASSO) regression, with the TCGA-LAML cohort as the discovery set and the independent Beat AML cohort as the external validation set.

Results

Transcriptomic analysis revealed that differentially expressed genes after VD-CAG treatment were mainly enriched in MAPK signaling and cell adhesion pathways. WGCNA identified five gene modules significantly correlated with treatment remission. We finally constructed a robust 11-gene prognostic signature ( TLN1, ARL15, PDZD2, ACER2, IGF2BP3, TMEM200A, DOCK1, SYTL4, CPNE8, FNDC3B , and MANBA ), which effectively stratified patients' overall survival. This signature showed strong predictive performance in both the discovery cohort (TCGA: HR=3.60, p =7.6e-10; 3-year AUC=0.79) and the independent validation cohort (Beat AML: HR=1.89, p =1.3e-3; 3-year AUC=0.83). Proteomic analysis identified 447 differentially expressed proteins between pre- and post-treatment samples, among which FNDC3B, a key protein in the prognostic signature, was significantly downregulated after VD-CAG intervention.

Conclusions

This study reveals the molecular alterations associated with VD-CAG treatment in non-M3 AML, and provides a validated 11-gene prognostic signature. These findings enhance our understanding of the response mechanisms of the VD-CAG regimen, and offer a tool to improve prognostic stratification and clinical decision-making for non-M3 AML patients.

Schlagwörter

Stichwörter der Autor:innen

VD-CAGacute myeloid leukemiaoverall survivalprognostic signaturetherapeutic response

Autor:innen und Institutionen

  • Department of Hematology, West China Hospital, Sichuan University, Chengdu, China.
  • Department of Hematology, The Affiliated Hospital of Southwest Medical University, Luzhou, China.

Zitieren

APA

Tang, J., Yang, K., Zhang, Y., Tang, Y., Yang, Y., Li, Q., Wang, X., & Gong, Y. (2026). Discovery and validation of a robust 11-gene prognostic signature via integrative multi-omics profiling in VD-CAG-treated non-M3 AML. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1801526

Vancouver

Tang J, Yang K, Zhang Y, Tang Y, Yang Y, Li Q, et al. Discovery and validation of a robust 11-gene prognostic signature via integrative multi-omics profiling in VD-CAG-treated non-M3 AML. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1801526

BibTeX
@article{Tang2026,
  author = {Tang, Jirui and Yang, Kun and Zhang, Ying and Tang, Yuqian and Yang, Yankun and Li, Qin and Wang, Xuemei and Gong, Yuping},
  title = {Discovery and validation of a robust 11-gene prognostic signature via integrative multi-omics profiling in VD-CAG-treated non-M3 AML},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1801526}
}
Kostenlos starten →